Semaglutide and Exercise Function in Obesity-Related HFpEF

In patients with obesity-related HFpEF, impaired 6MWD is most strongly associated with excess adiposity, congestion, and inflammation. Semaglutide-mediated improvements in HF-related symptoms, physical limitations, and exercise function were consistent across the spectrum of baseline 6MWD, observed as early as 20 weeks after the initiation of treatment, preceding maximal weight loss. The effects were consistent across subgroups. There was strong correlation between greater magnitude of weight loss and greater improvements in 6MWD. (Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity [STEP-HFpEF], NCT04788511; Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes [STEP-HFpEF DM], NCT04916470).

Authors

Institutions

Publication Details

Journal
JACC Heart Failure
Published
2025-10-04
DOI
https://doi.org/10.1016/j.jchf.2025.102660
Citations
1
Primary Topic
Cardiovascular Function and Risk Factors
Type
article
Field-Weighted Citation Impact
1.39
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Semaglutide and Exercise Function in Obesity-Related HFpEF

Sanjiv J. Shah, Mark C. Petrie, Mette Nygaard Einfeldt, Barry A. Borlaug et al.
1 citations
JACC Heart Failure
Cardiovascular Function and Risk Factors
1.39
article

Semaglutide and Exercise Function in Obesity-Related HFpEF

Sanjiv J. Shah, Mark C. Petrie, Mette Nygaard Einfeldt, Barry A. Borlaug, Julio E. Núñez, Khaja Chinnakondepalli, Mikhail Kosiborod, Dalane W. Kitzman, Afshin Salsali, Subodh Verma, Melanie Jane Davies, Karoline Liisberg, Shachi Patel, Javed Butler
article en
1 citations

Abstract

In patients with obesity-related HFpEF, impaired 6MWD is most strongly associated with excess adiposity, congestion, and inflammation. Semaglutide-mediated improvements in HF-related symptoms, physical limitations, and exercise function were consistent across the spectrum of baseline 6MWD, observed as early as 20 weeks after the initiation of treatment, preceding maximal weight loss. The effects were consistent across subgroups. There was strong correlation between greater magnitude of weight loss and greater improvements in 6MWD. (Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity [STEP-HFpEF], NCT04788511; Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes [STEP-HFpEF DM], NCT04916470).

JACC Heart FailureVol. 13(11)
Northwestern University (US), St. Michael's Hospital (CA), Mayo Clinic (US), University of Toronto (CA), Novo Nordisk (Denmark) (DK), University of Mississippi (US), Hospital Clínico Universitario de Valencia (ES), Mayo Clinic in Arizona (US), Saint Luke's Hospital (US), Mayo Clinic in Florida (US), Baylor Scott & White Health (US), NIHR Leicester Biomedical Research Centre (GB), Wake Forest University (US), University of Missouri–Kansas City (US), University of Glasgow (GB)
Openalex Percentile: Top 14%
Cardiovascular Function and Risk Factors
1.39
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.